US's civil trial against firms alleged to have contributed to the state's prescription opioid crisis will focus solely on Johnson & Johnson after the state reached settlements with two other firms targeted by the case. Purdue Pharma and Teva Pharmaceuticals, who were both initially defendants in the case, have agreed settlements of $270m and $85m respectively to end the action. Experts believe US's case against Johnson & Johnson, in which it will argue the company violated public nuisance law, could set a precedent for cases across the Oklahoma into the role of pharmaceutical firms in the opioid crisis.
Oklahoma's civil trial against firms alleged to have contributed to the state's prescription opioid crisis will focus solely on Johnson & Johnson after the state reached settlements with two other firms targeted by the case. Purdue Pharma and Teva Pharmaceuticals, who were both initially defendants in the case, have agreed settlements of $270m and $85m respectively to end the action. Experts believe Oklahoma's case against Johnson & Johnson, in which it will argue the company violated public nuisance law, could set a precedent for cases across the US into the role of pharmaceutical firms in the opioid crisis.